Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa Trial of Tetravalent Recombinant Norovirus Vaccine
NCT04563533Phase 2Completed
- Sponsor
- Zhifei Biological
- Start
- Aug 2020
- Primary completion
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tetravalent recombinant norovirus vaccine in acute gastroenteritis, norovirus infection, sponsored by Zhifei Biological. Started Aug 2020; status: completed.
02
Drugs
tetravalent recombinant norovirus vaccine
03
Conditions
acute gastroenteritisnorovirus infection
Beyond the preview
Go deeper on NCT04563533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563533.